NPHS1 Gene Nephrosis, Finnish Type Genetic Test in UAE | 2,800 AED | 2026 DHA Guidelines

Q1: What is the NPHS1 gene Finnish type nephrosis test and what does it diagnose?

The NPHS1 Genetic Test identifies pathogenic mutations in the NPHS1 gene responsible for congenital nephrotic syndrome of the Finnish type, enabling definitive molecular diagnosis and guiding clinical management decisions. This test sequences the entire coding region of the NPHS1 gene — which encodes the nephrin protein essential for kidney filtration — to detect single nucleotide variants, small insertions/deletions, copy number variations, and splice-altering mutations. Congenital nephrotic syndrome of the Finnish type is an autosomal recessive disorder most prevalent in Finnish populations but increasingly recognized in Middle Eastern and UAE cohorts due to consanguinity patterns. Early diagnosis through this test enables timely nephrology referral, albumin replacement strategies, and informed pre-transplant evaluation.

يكشف اختبار الحمض النووي الجيني NPHS1 بتقنية التسلسل من الجيل التالي عن الطفرات المسببة للمتلازمة الكلوية الخلقية من النوع الفنلندي بدقة تصل إلى 99.9%. هذا التحليل موجه للمرضى الذين يعانون من البيلة البروتينية غير المبررة في مرحلة الرضاعة أو لديهم تاريخ عائلي إيجابي للمرض الكلوي الوراثي.

Q2: Who should consider undergoing this NPHS1 genetic test in the UAE?

Individuals with a family history of congenital nephrotic syndrome, infants presenting with unexplained proteinuria or edema, and couples with known consanguinity planning pregnancy should consider this NPHS1 genetic test for accurate risk assessment. The test is also indicated for siblings of affected probands, pre-conception carrier screening in high-risk families, and individuals of Finnish descent exhibiting nephrotic-range proteinuria. In the UAE context, where autosomal recessive conditions are more prevalent due to cultural and demographic factors, proactive carrier screening is increasingly recommended by DHA guidelines. A pre-test genetic counseling session — included in our service protocol — helps draw a comprehensive pedigree chart and ensures fully informed decision-making.

يُنصح بهذا الفحص للأفراد الذين لديهم تاريخ عائلي للمتلازمة الكلوية الخلقية والأزواج ذوي صلة القرابة الذين يخططون للحمل. تشمل جلسة الاستشارة الوراثية رسم مخطط النسب العائلي لتحديد نمط الوراثة وتقدير المخاطر بدقة.

Q3: How long do results take and how should I interpret my NPHS1 test report?

Results are delivered within 3 to 4 weeks (21–28 days), and every report includes a clinically annotated interpretation classifying variants as pathogenic, likely pathogenic, or of uncertain significance per ACMG guidelines. Your DHA-certified report will detail the specific NPHS1 mutation(s) identified, zygosity status (homozygous or compound heterozygous), and a clear correlation with the Finnish-type congenital nephrotic syndrome phenotype where applicable. Post- telephonic guidance with a DHA-licensed physician is included to walk you through the implications — including prognosis, recommended specialist referrals (nephrologist, clinical geneticist), and family cascade testing options. Results are delivered securely via our encrypted patient portal in compliance with UAE PDPL data privacy regulations.

تُصدر النتائج خلال 3 إلى 4 أسابيع مع تقرير تفسيري سريري شامل وفقًا لإرشادات الكلية الأمريكية لعلم الوراثة الطبية. تشمل الخدمة استشارة هاتفية بعد الاختبار مع طبيب مرخص من هيئة الصحة بدبي لشرح النتائج وتوجيه الخطوات التالية.